Northwest Biotherapeutics (OTCMKTS:NWBO) Share Price Crosses Below 200-Day Moving Average - What's Next?

Key Points

• Technical signal: NWBO crossed below its 200‑day moving average of $0.24, trading as low as $0.1950 and last at $0.1975 on a volume of 2,410,066 shares.
• Business profile: Northwest Biotherapeutics is a clinical‑stage biotech developing personalized dendritic cell immunotherapies, with its lead candidate DCVax‑L in a global Phase III trial for glioblastoma.
• Valuation/metrics: The company has a market cap of $318.32 million, a negative P/E (-0.01) and a beta of -0.77, reflecting unprofitable status and historically low/negative correlation with the broader market.

Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO - Get Free Report)'s stock price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.24 and traded as low as $0.1950. Northwest Biotherapeutics shares last traded at $0.1975, with a volume of 2,410,066 shares changing hands.

Northwest Biotherapeutics Price Performance

The business's 50 day moving average price is $0.23 and its 200-day moving average price is $0.24. The company has a market cap of $318.32 million, a P/E ratio of -0.01 and a beta of -0.77.

Northwest Biotherapeutics Company Profile

Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company's proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient's tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.

The company's lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.